Loss of heterozygosity of FCY2 leading to the development of flucytosine resistance in Candida tropicalis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2506-2514

  Chen, Yen Ning ^a   Lo, Hsiu Jung ^b   Wu, Chia Chen ^a   Ko, Hui Ching ^a   Chang, Te Pin ^b   Yang, Yun Liang ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DERIVATIVE; CYTOSINE PERMEASE; FLUCYTOSINE; PURINE; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA TROPICALIS; CONTROLLED STUDY; DIPLOIDY; DRUG EXPOSURE; EPSILOMETER TEST; FUNGUS ISOLATION; HETEROZYGOSITY LOSS; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROGENY;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA TROPICALIS; CODON, NONSENSE; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; FLUCYTOSINE; HUMANS; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; NUCLEOBASE TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79956301191     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01777-10     Document Type: Article

References (45)

1. Andersen, M. P., Z. W. Nelson, E. D. Hetrick, and D. E. Gottschling. 2008. A genetic screen for increased loss of heterozygosity in Saccharomyces cerevisiae. Genetics 179:1179-1195.
2. Barchiesi, F., et al. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44:1578-1584.
3. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
4. Chai, Y. A., et al. 2007. Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. Med. Mycol. 45:435-439.
5. Chapeland-Leclerc, F., et al. 2005. Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob. Agents Chemother. 49:3101-3108.
6. Chen, K. W., Y. C. Chen, Y. H. Lin, H. H. Chou, and S. Y. Li. 2009. The molecular epidemiology of serial Candida tropicalis isolates from ICU patients as revealed by multilocus sequence typing and pulsed-field gel electrophoresis. Infect. Genet. Evol. 9:912-920.
7. Chen, P. L., et al. 17 December 2009. Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006. Mycoses [E-pub ahead of print.]
8. Cheng, M. F., et al. 2004. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48:33-37.
9. Chou, H. H., H. J. Lo, K. W. Chen, M. H. Liao, and S. Y. Li. 2007. Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. Diagn. Microbiol. Infect. Dis. 58:427-433.
10. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical Laboratory Standards Institute, Wayne, PA.
11. Coste, A., et al. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139-2156.
12. Coste, A. T., M. Karababa, F. Ischer, J. Bille, and D. Sanglard. 2004. TAC 1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652. (Pubitemid 40025121)
13. Cowen, L. E., et al. 2000. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182:1515-1522. (Pubitemid 30121114)
14. Desnos-Ollivier, M., et al. 2008. Clonal population of flucytosine-resistant candida tropicalis from blood cultures, Paris, France. Emerg. Infect. Dis. 14:557-565.
15. Diasio, R. B., J. E. Bennett, and C. E. Myers. 1978. Mode of action of 5-fluorocytosine. Biochem. Pharmacol. 27:703-707.
16. Dodgson, A. R., K. J. Dodgson, C. Pujol, M. A. Pfaller, and D. R. Soll. 2004. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48:2223-2227.
17. Dunkel, N., J. Blass, P. D. Rogers, and J. Morschhäuser. 2008. Mutations in the multidrug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840.
18. Edlind, T. D., and S. K. Katiyar. 2010. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob. Agents Chemother. 54:4733-4738.
19. Falagas, M. E., N. Roussos, and K. Z. Vardakas. 2010. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int. J. Infect. Dis. [Epub ahead of print.]
20. Florent, M., et al. 2009. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine- fluconazole cross-resistance in clinical isolates of Candida lusitaniae. Antimicrob. Agents Chemother. 53:2982-2990.
21. Forche, A., G. May, and P. T. Magee. 2005. Demonstration of loss of heterozygosity by single-nucleotide polymorphism microarray analysis and alterations in strain morphology in Candida albicans strains during infection. Eukaryot. Cell 4:156-165.
22. Franz, R., et al. 1998. Multiple molecular mechanisms contribute to a step-wise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
23. Hope, W. W., L. Tabernero, D. W. Denning, and M. J. Anderson. 2004. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob. Agents Chemother. 48:4377-4386.
24. Jacobsen, M. D., et al. 2008. Molecular phylogenetic analysis of Candida tropicalis isolates by multilocus sequence typing. Fungal Genet. Biol. 45:1040-1042.
25. Jacques, N., et al. 2010. Population polymorphism of nuclear mitochondrial DNA insertions reveals widespread diploidy associated with loss of heterozygosity in Debaryomyces hansenii. Eukaryot. Cell 9:449-459.
26. Niimi, K., et al. 2010. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 65:842-852.
27. Papon, N., et al. 2007. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob. Agents Chemother. 51:369-371.
28. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
29. Pfaller, M. A., et al. 2000. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-751.
30. Polak, A., and H. J. Scholer. 1975. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 21:113-130.
31. Reuss, O., A. Vik, R. Kolter, and J. Morschhauser. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. (Pubitemid 39335889)
32. Sherman, F. 2002. Getting started with yeast. Methods Enzymol. 350:3-41. (Pubitemid 34619482)
33. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179.
34. Waldorf, A. R., and A. Polak. 1983. Mechanisms of action of 5-fluorocytosine. Antimicrob. Agents Chemother. 23:79-85.
35. Wang, J. S., S. Y. Li, Y. L. Yang, H. H. Chou, and H. J. Lo. 2007. Association between fluconazole susceptibility and genetic relatedness among Candida tropicalis isolates in Taiwan. J. Med. Microbiol. 56:650-653.
36. Warnock, D. W. 2007. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 48:1-12. (Pubitemid 46280129)
37. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
38. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
39. Wu, J. M., et al. 2007. Solution structure of a novel D-naphthylalanine substituted peptide with potential antibacterial and antifungal activities. Biopolymers 88:738-745.
40. Xess, I., N. Jain, F. Hasan, P. Mandal, and U. Banerjee. 2007. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 35:256-259. (Pubitemid 47222273)
41. Yang, Y. L., et al. 2010. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. Med. Mycol. 48:328-334.
42. Yang, Y. L., Y. A. Ho, H. H. Cheng, M. Ho, and H. J. Lo. 2004. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect. Control Hosp. Epidemiol. 25:60-64.
43. Yang, Y. L., S. Y. Li, H. H. Cheng, and H. J. Lo. 2005. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn. Microbiol. Infect. Dis. 51:179-183.
44. Yang, Y. L., and H. J. Lo. 2001. Mechanisms of antifungal agent resistance. J. Microbiol. Immunol. Infect. 34:79-86.
45. Yang, Y. L., et al. 2008. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2006. Diagn. Microbiol. Infect. Dis. 61:175-180.